Article
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Signal transduction and targeted therapy - 17 Jun 2025
Ruan Dan-Yun, Wu Hao-Xiang, Xu Ye, Munster Pamela N, Deng Yanhong, Richardson Gary, Yan Dong, Lee Myung-Ah, Lee Keun-Wook, Pan Hongming, Hager Steven, Li Xingya, Wei Shaozhong, Hou Xinfang, Underhill Craig, Millward Michael, Nordman Ina, Zhang Jingdong, Shan Jianzhen, Han Guohong, Grewal Jaspreet, Gadgeel Shirish M, Sanborn Rachel E, Huh Seok Jae, Hu Xiaohua, Zhang Yihong, Xiang Ziyong, Luo Laisheng, Xie Xiaoxi, Shi Zhe, Wang Yaolin, Zhang Ling, Wang Feng, Xu Rui-Hua
Abstract excerpt
Mutations in the KRAS gene have long been implicated in the pathogenesis of colorectal cancer (CRC). KRAS G12C inhibitors overcome the "undruggable" challenge, enabling precision therapy. Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials. We conducted an open-label, nonrandomized phase II...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.